Comparison of intraperitoneal and subcutaneous epoetin alfa in peritoneal dialysis patients

Peritoneal Dialysis International

Volumn 19, Issue 6, 1999, Pages 578-582

  Johnson, Curtis A ^a,b   Wakeen, Maureen ^b   Taylor III, Claude A ^c   Zimmerman, Stephen W ^b   Burkart, John ^d   Bhattacharya, Abhik ^a   Kosorok, Michael R ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c UNIVERSITY OF TEXAS AT EL PASO   (United States)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Epoetin alfa; Hematocrit; Intraperitoneal administration; Subcutaneous administration

Indexed keywords

IRON; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; FEMALE; FOLLOW UP; HEMATOCRIT; HUMAN; IRON THERAPY; MALE; OUTPATIENT DEPARTMENT; PERITONEAL CAVITY; PERITONEAL DIALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

EID: 0033402645     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686089901900613     Document Type: Article

References (13)

1. United States Renal Data System. USRDS 1998 annual data report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1998.
2. Bargman JM, Jones JE, Petro JM. The pharmacokinetics of intraperitoneal erythropoietin administered undiluted or diluted in dialysate. Perit Dial Int 1992; 12:369-72.
3. Ateshkadi A, Johnson CA, Oxton LL, Hammond TG, Bohenek WS, Zimmerman SW. Pharmacokinetics of intraperitoneal, intravenous, and subcutaneous recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1993; 21:635-42.
4. Taylor CA, Kosorok MR, Zimmerman SW, Johnson CA. Pharmacokinetics of intraperitoneal epoetin alfa in patients on peritoneal dialysis using an 8-hour "dry dwell" dosing technique. Am J Kidney Dis 1999; 34: 657-62.
5. Lui SF, Chung WW, Leung CB, Chan K, Lai KN. Pharmacokinetics and pharmacodynamics of subcutaneous and intraperitoneal administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Clin Nephrol 1990; 33:47-51.
6. Hussein M, Abraham G, Roujouleh H. Treatment of anemia by intraperitoneal (IP) administration of recombinant human erythropoietin in intermittent peritoneal dialysis (IPD) (Abstract). Perit Dial Int 1990; 10(Suppl 1):S80.
7. Sachdeva JS, Chu SM, Bargman JM. Clinical experience with intraperitoneal erythropoietin in adult patients on peritoneal dialysis (Abstract). Perit Dial Int 1997; 17(Suppl 1):S99.
8. Reddingius RE, de Boer ASN, Schröder CH, Willems JL, Monnens LAH. Increase of the bioavailability of intraperitoneal erythropoietin in children on peritoneal dialysis by administration in small dialysis bags. Perit Dial Int 1997; 17:467-70.
9. Steele BT, Vigneux A. Intraperitoneal erythropoietin treatment of children with chronic renal failure. Pediatr Nephrol 1995; 9:359-60.
10. Brandt JR, Hansen C, Watkins SL. Intraperitoneal (IP) use of recombinant human erythropoietin (rHuEPO) in children: a pharmacokinetic and pharmacodynamic study (Abstract). J Am Soc Nephrol 1997; 8:133A.
11. Fisher LD, van Belle G. Biostatistics: a methodology for the health sciences. New York: Wiley, 1993:323-6.
12. National Kidney Foundation. Dialysis Outcomes Quality Initiative clinical practice guidelines for the treatment of anemia of chronic renal failure. Am J Kidney Dis 1997; 30(Suppl 3):S192-237.
13. Kaufman JS, Reda DJ, Fye CL, Goldfarb DS, Henderson WG, Kleinman JG, et al. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. N Engl J Med 1998; 339:578-83.